Lepu Medical Technology (Beijing) Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
The Company has learned today that its controlling subsidiary, Shanghai Minwei Biotechnology Co., Ltd. (hereinafter referred to as "Shanghai Minwei"), has independently developed the dual-target small interfering RNA (siRNA) drug MWX205 injection, which has officially submitted a Phase I clinical trial application to the Human Research Ethics Committee (HREC) in Australia and has received approval. The details are announced as follows: